Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
UCBCares: Providing Dedicated Patient Support
Clinical studies at UCB: How are medicines made and tested?
Twitter Feed
-
Based on a recent UCB survey, almost 1 in 5 patients living with #osteoporosis reported having to reduce their working hours, and one in 8 said the condition meant they had to give up work completely. https://t.co/PB9HKY1KXm https://t.co/sCYjE5yE5O
— UCB News (@ucb_news) 10.01.2020 -
Is #osteoporosis a neglected condition? We asked patients https://t.co/PB9HKYjlOU https://t.co/oULVYLxtGq
— UCB News (@ucb_news) 07.01.2020 -
We’re counting down to 2020 - not just a new day or a new year but a new decade! Stay tuned for news on the 2020’s promising innovations #InspiredByPatients #DrivenByScience https://t.co/JNnjvbLbHf
— UCB News (@ucb_news) 30.12.2019
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
